Search results for "BoP"

showing 10 items of 284 documents

Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis

2018

AbstractWe have recently demonstrated that riboflavin (Rf) functions as unconventional bioorthogonal photocatalyst for the activation of PtIV prodrugs. In this study, we show how the combination of light and Rf with two PtIV prodrugs is a feasible strategy for light-mediated pancreatic cancer cell death induction. In Capan-1 cells, which have high tolerance against photodynamic therapy, Rf-mediated activation of the cisplatin and carboplatin prodrugs cis,cis,trans-[Pt(NH3)2(Cl)2(O2CCH2CH2CO2H)2] (1) and cis,cis,trans-[Pt(NH3)2(CBDCA)(O2CCH2CH2CO2H)2] (2, where CBDCA = cyclobutane dicarboxylate) resulted in pronounced reduction of the cell viability, including under hypoxia conditions. Such …

0301 basic medicineProgrammed cell deathLightOrganoplatinum CompoundsDNA damageCell SurvivalRiboflavinlcsh:MedicinePlatinum prodrugs DNA bioorthogonal photocatalysis riboflavinAntineoplastic AgentsArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumormedicineHumansProdrugsViability assaylcsh:ScienceCisplatinMultidisciplinaryChemistrylcsh:RProdrugPhotochemical ProcessesChemical biologyCarboplatinCoordination chemistry030104 developmental biologySettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisBiophysicslcsh:QBioorthogonal chemistrymedicine.drug
researchProduct

Inflammation and the coagulation system in tuberculosis: Tissue Factor leads the dance

2016

Mycobacterium tuberculosis, the causative agent of tuberculosis, drives the formation of granulomas, structures in which both immune cells and the bacterial pathogen cohabit. The most abundant cells in granulomas are macrophages, which contribute as both cells with bactericidal activity and as targets for M. tuberculosis infection and proliferation during the entire course of infection. The mechanisms and factors involved in the regulation and control of macrophage microenvironment-specific polarization and plasticity are not well understood, as some granulomas are able to control bacteria growth and others fail to do so, permitting bacterial spread. In this issue of the European Journal of…

0301 basic medicineTuberculosisMacrophageTuberculosiImmunologyInflammationMacrophages; Mycobacterium tuberculosis; Tissue Factor; Tuberculosis; Animals; Bacteremia; Cell Differentiation; Fibrin; Host-Pathogen Interactions; Humans; Immunity Innate; Lung; Macrophages; Mice; Mice Knockout; Mycobacterium tuberculosis; Pneumonia; Thromboplastin; Tuberculoma; Tuberculosis Pulmonary; Blood Coagulation; Immunology; Immunology and Allergy; Medicine (all)BacteremiaMycobacterium tuberculosiThromboplastinMycobacterium tuberculosis03 medical and health sciencesTissue factorMiceImmune systemImmunitymedicineMacrophageImmunology and AllergyAnimalsHumansTuberculomaBlood CoagulationLungTuberculosis PulmonaryMice KnockoutFibrinCord factorbiologyAnimalMedicine (all)MacrophagesCell DifferentiationMycobacterium tuberculosisPneumoniabiology.organism_classificationmedicine.diseaseImmunity Innate3. Good healthTissue FactorHost-Pathogen Interaction030104 developmental biologyImmunologyHost-Pathogen Interactionsmedicine.symptomHumanEuropean Journal of Immunology
researchProduct

Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking

2017

Objective— Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. Approach and Results— Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF + microvesicles. T…

0301 basic medicinedynaminsIntegrin alpha4CellCardiorespiratory Medicine and Haematology030204 cardiovascular system & hematologyIntegrin alpha4beta1Inbred C57BLTransgenicMicechemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateCell-Derived MicroparticlesReceptors2.1 Biological and endogenous factorsfibrinGene Knock-In TechniquesAetiologyPhospholipidsTumorbiologyChemistryADP-Ribosylation FactorsHematologyPhosphatidylserineCell biologyProtein Transportmedicine.anatomical_structurePhenotypeProteomeextracellular vesiclesCardiology and Cardiovascular MedicinePurinergic P2X7BiotechnologySignal TransductionGenotypeproteomeClinical SciencesIntegrinMice TransgenicFactor VIIaTransfectionExtracellular vesiclesFibrinArticleCell LineThromboplastin03 medical and health sciencesTissue factorCell Line TumormedicineAnimalsHumansBlood CoagulationMacrophagesThrombosisMice Inbred C57BL030104 developmental biologyCardiovascular System & HematologyADP-Ribosylation Factor 6biology.proteinReceptors Purinergic P2X7
researchProduct

PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospec…

2015

There are no univocal opinions on the role of genetic thrombophilia on splanchnic vein thrombosis (SVT). We defined genetic thrombophilia the presence of one of these thrombophilic genetic factors (THRGFs): PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and prothrombin 20210A.To evaluate the frequencies of these THRGFs in SVT patients, we analyzed individual data of 482 Caucasian patients, recruited from 2000 to 2014 in three prospective studies. SVT was defined as the presence of thrombosis of portal (PVT), mesenteric (MVT), splenic (SPVT), cava (CT), and hepatic vein (Budd Chiari syndrome, BCS). Pre-hepatic SVT (pre-HSVT) was defined as PVT with or without MVT/SPVT, without BCS. Post-hepatic SV…

0301 basic medicinemedicine.medical_specialtyHepatologybiologybusiness.industry030204 cardiovascular system & hematologymedicine.diseaseThrombophiliaGastroenterologyThrombosisSurgeryPortal vein thrombosis03 medical and health sciences030104 developmental biology0302 clinical medicineSplanchnic vein thrombosisInternal medicineMethylenetetrahydrofolate reductaseBudd–Chiari syndromebiology.proteinMedicineOriginal ArticlebusinessProspective cohort studyMyeloproliferative neoplasm
researchProduct

Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

2016

<b><i>Objective:</i></b> To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency. <b><i>Methods:</i></b> In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP). <b><i>Results:</i></b> Mean APTT was significantly shortened in HAE-C1-INH type I (p < 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p < 0.0001) compared to the HP. APTT was shorten…

0301 basic medicinemedicine.medical_specialtyImmunologyAcquired angioedemaGastroenterologyC1-inhibitorDiagnosis Differential03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansImmunology and Allergyheterocyclic compoundsProspective StudiesAngioedemaProspective cohort studyBlood CoagulationBlood coagulation testAngioedemamedicine.diagnostic_testbiologybusiness.industryAngioedemas HereditaryComplement C4General Medicinerespiratory systembacterial infections and mycosesrespiratory tract diseases030104 developmental biologyCoagulationPredictive value of testsAnesthesiaImmunologybiology.proteinPartial Thromboplastin TimeBlood Coagulation Testsmedicine.symptombusinessComplement C1 Inhibitor ProteinBiomarkerscirculatory and respiratory physiologyPartial thromboplastin timeInternational Archives of Allergy and Immunology
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness

2020

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Plasma AntithrombinSeverity of Illness IndexAntithrombinsCoronavirus Disease 2019medicineHumansThrombophiliaProspective StudiesPlasma Antithrombin Coronavirus Disease 2019 COVID-19business.industryHeparinSARS-CoV-2AntithrombinAnticoagulantsCOVID-19ThrombosisHematologyDisseminated Intravascular CoagulationVirologyCross-Sectional StudiesbusinessCardiology and Cardiovascular Medicinemedicine.drug
researchProduct

Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

2021

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…

2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopenia
researchProduct

Controlled polyhedral sweeping processes: existence, stability, and optimality conditions

2021

This paper is mainly devoted to the study of controlled sweeping processes with polyhedral moving sets in Hilbert spaces. Based on a detailed analysis of truncated Hausdorff distances between moving polyhedra, we derive new existence and uniqueness theorems for sweeping trajectories corresponding to various classes of control functions acting in moving sets. Then we establish quantitative stability results, which provide efficient estimates on the sweeping trajectory dependence on controls and initial values. Our final topic, accomplished in finite-dimensional state spaces, is deriving new necessary optimality and suboptimality conditions for sweeping control systems with endpoint constrain…

49M25Applied Mathematics[MATH.MATH-OC] Mathematics [math]/Optimization and Control [math.OC]Existence of feasible solutions510Sweeping processQualitative stabilityOptimal controlMoving polyhedraOptimization and Control (math.OC)necessary optimality and suboptimality conditionsDiscrete approximationsFOS: MathematicsNecessary optimality and suboptimality conditions 2010 MSC: 49J5249J52 49J53 49K24 49M25[MATH.MATH-OC]Mathematics [math]/Optimization and Control [math.OC]49K2449J52Mathematics - Optimization and ControlAnalysis49J53
researchProduct

Two New Alternatives to the Conventional Arm-in-Cage Test for Assessing Topical Repellents

2021

Abstract European guidelines for testing attractant and repellent efficacy (i.e., Product type 19 [PT19]) have been in revision since 2017. A key topic of discussion is the current approach to evaluating topical repellents. The European Chemical Agency has stated field testing should be avoided because of mosquito-borne disease risks. However, the most common laboratory method, the arm-in-cage (AIC) test, may limit the reliable extrapolation of lab results to field conditions. This study’s main goal was to assess alternative laboratory methods for evaluating topical mosquito repellents that use mosquito landing rates more representative of those in the field. The study took place at three E…

AcademicSubjects/SCI01382Aedes albopictus030231 tropical medicineDEETToxicology03 medical and health sciencesroom test0302 clinical medicineTesting protocolsAedesVector Control Pest Management Resistance RepellentsAnimalsHumansAcademicSubjects/MED00860030304 developmental biology0303 health sciencesLaboratory methodsGeneral Veterinarybiologylanding rateAedes albopictusbiology.organism_classificationTest (assessment)testing protocolsInfectious DiseasesbioassayInsect RepellentsInsect ScienceBiological AssayParasitologyField conditionsJournal of Medical Entomology
researchProduct